Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03401385 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
A Phase 1 study of Non-Small Cell Lung Cancer and Triple Negative Breast Cancer, sponsored by Daiichi Sankyo Co..
- Active
- Registry status
- Phase 1
- Development phase
- 890
- Enrollment target
- 18
- Study locations
NCT03401385 is a Phase 1 study of Non-Small Cell Lung Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Daiichi Sankyo Co.. The registered enrollment target is 890 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (35% higher). The trial reports 18 study locations across 12 states.
The verdict
NCT03401385, a Phase 1 study of Non-Small Cell Lung Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 890 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: * Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a * Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are located in both the United States and Japan. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: * they withdraw * their disease gets worse * they experience unacceptable side effects. The primary purpose of the sub-study is to compare the effectiveness of steroid versus non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants receiving DS-1062a. The sub-study is a randomized study that will include approximately 76 participants enrolling into the Dose Expansion part.
Conditions Studied
Interventions
- DRUG Datopotamab Deruxtecan (Dato-DXd)
- DRUG Steroid Containing Mouthwash
- OTHER Non-Steroid Containing Mouthwash
Study Locations (18)
Texas
- MD Anderson Cancer Center - Houston
- Next Oncology - San Antonio
- START Oncology - San Antonio
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Tisch Cancer Institute, Icahn School of Medicine - New York
- Memorial Sloan-Kettering Cancer Center - New York
Tokyo
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research - Koto-Ku
- Showa Medical University Hospital - Shinagawa-Ku
Other
- National Cancer Center Hospital - Chūōku
- National Cancer Center Hospital East - Kashiwa
California
- University of California, Los Angeles - Los Angeles
District of Columbia
- Johns Hopkins Sibley Memorial Hospital - Washington D.C.
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03401385
The ClinicalTrials.gov registry entry for NCT03401385 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 890 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (35% higher). The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Datopotamab Deruxtecan (Dato-DXd) is the first listed.
NCT03401385 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Texas, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT03401385 about?
NCT03401385 is a clinical study titled "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)". This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: * Dose Escalation: To investigat...
What is the current status of trial NCT03401385?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 890 participants. The study started on 2018-01-31. Estimated completion is 2027-01-01.
What conditions does trial NCT03401385 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, Hormone Receptor-Positive Breast Cancer.
What interventions are being tested in trial NCT03401385?
The interventions under investigation include: Datopotamab Deruxtecan (Dato-DXd) (DRUG), Steroid Containing Mouthwash (DRUG), Non-Steroid Containing Mouthwash (OTHER).
Who is sponsoring clinical trial NCT03401385?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03401385 being conducted?
This trial has 18 study locations across California, District of Columbia, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.